Earnings
-
Courtesy of Intuitive
Intuitive execs cast wary eye on potential Trump tariffs
The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.
By Susan Kelly • Jan. 24, 2025 -
Permission granted by Abbott
Abbott expects to launch first PFA device outside of the US this year
CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.
By Elise Reuter • Jan. 22, 2025 -
Permission granted by Johnson & Johnson
J&J coordinating with FDA on US pause of Varipulse due to safety risks
Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will restart after halting procedures in early January.
By Ricky Zipp • Jan. 22, 2025 -
Justin Sullivan via Getty Images
Trump’s return to office brings uncertainty for medtech industry
With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.
By Ricky Zipp • Dec. 18, 2024 -
Bruce Bennett via Getty Images
Henry Schein to acquire medical supplier Acentus
Acentus, which specializes in supplying glucose sensors to patients’ homes, continues Henry Schein’s recent focus on building its homecare medical supplies business.
By Ricky Zipp • Nov. 21, 2024 -
Courtesy of Medtronic
Medtronic’s ablation sales slowed by PFA supply issues
CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues that have now been resolved.
By Ricky Zipp • Nov. 19, 2024 -
Courtesy of Boston Scientific
Boston Scientific closes $3.7B Axonics deal after lengthy review
Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission requested more information.
By Ricky Zipp • Nov. 15, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
By Ricky Zipp • Nov. 13, 2024 -
Retrieved from Aerial Lens on October 10, 2024
Baxter to restart second IV fluid production line at hurricane-damaged site
CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter from Hurricane Helene's disruption.
By Susan Kelly • Nov. 11, 2024 -
Courtesy of Exact Sciences
Exact Sciences’ forecast cut shocks analysts
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.
By Nick Paul Taylor • Nov. 8, 2024 -
Courtesy of Tandem Diabetes Care
Tandem, Insulet tout Type 2 expectations as tech attracts new users
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while Tandem plans to file a Type 2 submission by year’s end.
By Ricky Zipp • Nov. 8, 2024 -
Courtesy of Siemens Healthineers
Siemens Healthineers confident it can cope with Trump tariffs
CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump returns to the White House.
By Nick Paul Taylor • Nov. 7, 2024 -
Permission granted by Politan Capital Management
Masimo, amid leadership transition, targets cost reductions
Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not spun off.
By Susan Kelly • Nov. 6, 2024 -
Courtesy of Medtronic
Baxter, Medtronic, Insulet to wrap up medtech earnings
Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation device.
By Elise Reuter • Nov. 5, 2024 -
Courtesy of Integra LifeSciences Holdings Corporation
Integra Lifesciences names Mojdeh Poul as CEO
Poul will take over the company in January after spending 11 years with 3M and working at Medtronic and Boston Scientific.
By Nick Paul Taylor • Nov. 5, 2024 -
Permission granted by Zimmer Biomet
Stryker, Zimmer outline different M&A strategies
Stryker CEO Kevin Lobo told investors M&A will be the “number one use of our cash going forward,” while Zimmer Biomet CEO Ivan Tornos emphasized internal product development for growth.
By Elise Reuter • Oct. 30, 2024 -
Patrik Stollarz / Staff via Getty Images
Philips cuts sales forecast after ‘significant deterioration’ in China
CEO Roy Jakobs expects the slump to continue into 2025, driven by China’s anti-corruption measures.
By Nick Paul Taylor • Oct. 28, 2024 -
Permission granted by Dexcom
Dexcom chief commercial officer to retire
Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce restructuring.
By Elise Reuter • Oct. 25, 2024 -
Courtesy of Edwards Lifesciences
Edwards’ TAVR sales faced ongoing hospital constraints in Q3
Hurt by a slowdown in procedures for its heart valve replacement devices, Edwards said it is working with hospitals to manage workflow challenges.
By Susan Kelly • Oct. 25, 2024 -
Courtesy of Boston Scientific
Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared to a year ago.
By Susan Kelly • Oct. 23, 2024 -
Courtesy of Intuitive Surgical
Intuitive readies da Vinci 5 for broader launch after placing 110 robots in Q3
BTIG analysts wrote that installations of Intuitive’s new robotic surgery system are “well ahead of lofty” expectations.
By Susan Kelly • Oct. 18, 2024 -
Permission granted by Abbott
Abbott CEO sees ‘mass market potential’ for CGMs
Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.
By Ricky Zipp • Oct. 16, 2024 -
Courtesy of Johnson & Johnson
J&J’s recent medtech buys help to prop up devices unit
Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.
By Ricky Zipp • Oct. 15, 2024 -
Mario Tama via Getty Images
J&J, Abbott and Intuitive kick off latest medtech earnings season
From pulsed field ablation to diabetes tech and surgical robots, the updates will provide an early look at how key medtech markets performed last quarter.
By Nick Paul Taylor • Oct. 14, 2024 -
Courtesy of Medtronic
Medtronic: Diabetes strategy hasn’t changed amid Abbott partnership
Que Dallara, president of Medtronic’s diabetes unit, said the company still believes in its diabetes technology, but the partnership “allows us to tap into the largest CGM install base in the world.”
By Ricky Zipp • Aug. 20, 2024
